In the strategy targeting TAM recruitment in metastatic CRC therapy, some chemokine inhibitors are considered as targets, e.g., CXCR4-CXCL12 inhibitors alone or with durvalumab (anti-PD-L1 Ab) (phase I) [176]; C-C motif chemokine receptor 2/5 (CCR2/5) (agent BMS813160) with nivolumab (anti-PD1 Ab); or paclitaxel (phase I/II) [62] and pembrolizumab (CCR5 antagonist) (phase I completed) [187,188]. The gene discussed is CCR2; the disease is colorectal carcinoma.